These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 20187016)

  • 21. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma.
    Giovanella L; Ceriani L; Ghelfo A; Keller F
    Clin Chem Lab Med; 2005; 43(8):843-7. PubMed ID: 16201895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence, clinical significance and prognostic value of anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid carcinoma: a retrospective study.
    Pedrazzini L; Baroli A; Lomuscio G; Marzoli L
    Minerva Endocrinol; 2009 Sep; 34(3):195-203. PubMed ID: 19859043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?
    Rosario PW; Mourão GF; dos Santos JB; Calsolari MR
    Thyroid; 2014 Mar; 24(3):533-6. PubMed ID: 24067080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment.
    Bachelot A; Leboulleux S; Baudin E; Hartl DM; Caillou B; Travagli JP; Schlumberger M
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):376-9. PubMed ID: 15730423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prospective therapy study in differentiated thyroid carcinoma].
    Gemsenjäger E; Heitz P; Martina B
    Schweiz Med Wochenschr; 1995 Nov; 125(46):2226-36. PubMed ID: 8525342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.
    Korkmaz MH; Öcal B; Saylam G; Çakal E; Bayır Ö; Tutal E; Tatar EÇ
    Langenbecks Arch Surg; 2017 Mar; 402(2):235-242. PubMed ID: 28224278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroglobulin-guided (131)I ablation in low-risk differentiated thyroid carcinoma: is the yardstick accurate enough?
    Giovanella L
    Head Neck; 2011 Sep; 33(9):1379-80; author reply 1380-1. PubMed ID: 21739512
    [No Abstract]   [Full Text] [Related]  

  • 31. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.
    Frasoldati A; Pesenti M; Gallo M; Caroggio A; Salvo D; Valcavi R
    Cancer; 2003 Jan; 97(1):90-6. PubMed ID: 12491509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.
    Bonnet S; Hartl D; Leboulleux S; Baudin E; Lumbroso JD; Al Ghuzlan A; Chami L; Schlumberger M; Travagli JP
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1162-7. PubMed ID: 19116234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
    Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
    Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
    Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
    Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
    Bal CS; Kumar A; Pant GS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
    Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
    Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
    Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
    Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
    Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
    J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low versus high activity radioiodine remnant ablation for differentiated thyroid carcinoma with gross extrathyroidal extension invading only strap muscles.
    Park SY; Kim HI; Choi JY; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Ahn SH; Kim K; Jeong JG; Kim SW; Chung JH; Kim TH
    Oral Oncol; 2018 Sep; 84():41-45. PubMed ID: 30115474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
    Mourão GF; Rosario PW; Calsolari MR
    Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.